key: cord-0853791-8tj4elt7
authors: Lleo, Ana; Cazzagon, Nora; Rigamonti, Cristina; Cabibbo, Giuseppe; Lai, Quirino; Muratori, Luigi; Carbone, Marco
title: CLINICAL UPDATE ON RISKS AND EFFICACY OF ANTI-SARS-COV-2 VACCINES IN PAZIENTS WITH AUTOIMMUNE HEPATITIS AND SUMMARY OF REPORTS ON POST-VACCINATION LIVER INJURY
date: 2022-03-28
journal: Dig Liver Dis
DOI: 10.1016/j.dld.2022.03.014
sha: e9380901f1ee416dc96fcf72bf05c6eea8dd481a
doc_id: 853791
cord_uid: 8tj4elt7

Patients with liver diseases, especially those with cirrhosis, have an increased mortality risk when infected by SARS-CoV-2 and therefore anti-SARS-CoV-2 vaccine has been recommended by leading Scientific Associations for all patients with chronic liver diseases. However, previous reports have shown a reduced antibody response following the full course of vaccination in immunosuppressed patients, including liver transplant recipients and several rheumatic diseases. This document, drafted by an expert panel of hepatologists appointed by the Italian Association for the Study of the Liver (AISF), aims to present the updated scientific data on the safety and efficacy of anti-SARS-CoV-2 mRNA vaccines in patients with autoimmune hepatitis (AIH). Furthermore, given the recent reports of sporadic cases of AIH-like cases following anti-SARS-CoV-2 mRNA vaccines, we summarize available data. Finally, we provide experts recommendations based on the limited data available.

Patients with chronic liver diseases (CLD), especially those with cirrhosis, have an increased mortality risk when infected by SARS-CoV-2 [1] . One of the largest international studies currently available, showed an observed mortality of 32% in patients with cirrhosis compared to 8% in those without [2] . Therefore, the European Association for the Study of the Liver (EASL) has recommended vaccination against SARS-CoV-2 for all patients with CLD [3] . Although contrasting data have been published, patients with AIH with or without cirrhosis under immunosuppressive therapy represent an at-risk category of developing severe COVID-19 when infected [4, 5] .

Therefore, based on the data available, the benefit of anti-SARS-CoV-2 vaccination outweighs the potential risk for disease exacerbation in AIH.

Although the registration trials of mRNA vaccines enrolled patients with CLD (217 patients in Pfizer trial and 196 patients in Moderna trial), subjects under immunosuppressive therapy were excluded. A recent study by Thuluvath and colleagues found that 75% of patients with CLD without cirrhosis and 77% of patients with cirrhosis had adequate antibody response to anti-SARS-CoV2 vaccines [6] . The authors included 233 patients with CLD with 61 being affected by immune mediated liver diseases, including AIH, primary biliary cholangitis, and primary sclerosing cholangitis. Also 62 patients were liver transplant (LT) recipients, 79 had cirrhosis, and 92 had CLD without cirrhosis. Antibody levels were undetectable in 11 patients who had LT, 3 with cirrhosis, and 4 without liver cirrhosis. LT and treatment with two or more immunosuppressive drugs were associated with poor antibody responses. However, only 3 patients out of 18 with undetectable antibody were AIH patients on immunosuppression (2 on prednisone plus mycophenolate mofetil (MMF) and 1 on prednisone plus azathioprine).

Reports have shown a reduced antibody response following the full course of vaccination in liver transplant recipients [7] . It has also been formerly demonstrated that specific drugs (i.e. methotrexate, abatacept, and rituximab) reduced the immune response to influenza or pneumococcal vaccines in a number of different rheumatic diseases [8] [9] [10] . The efficacy of anti-SARS-CoV-2 vaccination in preventing COVID-19 in patients with AIH on immunosuppressive therapies [11, 12] , as well as the risk of disease reactivation after anti-SARS-CoV-2 vaccination, have been poorly investigated. Similarly, cellular immunity to SARS-CoV-2 in AIH patients has not been studied.

The American College of Rheumatology (ACR) has recently proposed a guidance [13] suggesting a short-term withdrawal of methotrexate, JAK inhibitors, abatacept, and MMF, and deferral of rituximab and cyclophosphamide infusion if possible before anti SARS-Cov-2 vaccination, according to rheumatic disease activity. However, there is no solid evidence as to whether it is appropriate or not to suspend or reduce the dose of immunosuppressive drugs immediately before or following the administration of the vaccine in AIH patients. Importantly, this strategy may be potentially associated with an increased risk of AIH reactivation particularly dangerous in patients with cirrhosis. Of interest, high doses of MMF and rituximab remain independent predictors of failure to develop an antibody response after vaccination in rheumatic diseases [14] ; however, no data are available in AIH. At the present time, the available data do not justify withdraw or reduction of immunosuppression before or immediately after vaccination in patients with AIH.

Finally, no clear evidence of reactivation of AIH after anti-SARS-CoV-2 vaccination has been reported in the literature. Interestingly, the presence of significant fibrosis at the liver histology of a small number of newly diagnosed AIH following anti-SARS-CoV-2 vaccination might suggest the possibility of disease reactivation [15] [16] [17] . However, until new multicenter studies are available there is no current indication for routine testing of transaminases levels in AIH patients after vaccination.

The COVID-19 pandemics has necessitated the development and registration of several vaccines in record time. The monitoring for safety, side effect and efficacy is ongoing in the post-marketing surveillance. Recent reports inform on the possible occurrence of immune mediated hepatitis or AIH-like disease in predisposed individuals. Autoimmunity is widely accepted to develop in genetically predisposed individuals and some polymorphisms have been identified in AIH [18] ; unfortunately, they are not yet of clinical use and cannot be of help to identify individuals at risk.

Considering that 58% of the world population has received at least one dose of anti-SARS-CoV-2 vaccine, with 9.2 billion doses been administered globally, it is unclear whether this is a pure coincidence rather than a causality.

The fact that someone developed immune-mediated acute hepatitis after vaccination does not necessarily mean that this was caused by the vaccine..

has recently started an assessment following the very small number of cases reported after vaccination with Spikevax® and Comirnaty® (known as Moderna and Pfizer vaccines, respectively) in the medical literature and EudraVigilance (www.ema.europa.eu). Further data and analyses have been requested from the marketing authorization holder to support the ongoing assessment by PRAC. Given the small number of cases currently reported, the issue seems to be rare; however, specific studies should be performed to define the number and severity of cases.

At the time these recommendations are drafted, 17 reports have been published in the medical literature that overall include 31 cases of suspected AIH-like triggered by the vaccine ( Table 1) .

Patients were more often women (F:M 21:10), age ranging from 32 to 89 years old (median 58 years). In eleven cases a pre-existent autoimmune condition (i.e., seven Hashimoto thyroiditis, one primary biliary cholangitis, two rheumatoid arthritis, one systemic lupus erythematosus) is reported. Two patients had experienced COVID-19 infection before the vaccine. All except four presented with an acute onset of AIH-like with jaundice. All patients underwent liver biopsy and in six of them fibrosis was already present, which might suggest that they had a previous liver disease, possibly an undiagnosed AIH. All were treated with steroid therapy, and all improved the liver function tests (LFTs), although details on the biochemical response are not thoroughly reported.

Adverse effects of the vaccine are possible, and abnormal liver function tests following vaccination represent an important clinical issue. AIH is a relatively rare, chronic immune-mediated liver disease, which develops in genetically predisposed individuals following environmental triggers; viral infections and drug exposures have been suggested to trigger the disease, but not definitive evidence is available [19, 20] . AIH-like onset after vaccination -other than anti-SARS-CoV-2 -has been also previously reported [21] . However, even if it can be speculated that the vaccines can disturb self-tolerance and trigger autoimmune responses through cross-reactivity with host cells, it might be hard to definitively state that AIH is induced by a vaccine. Considering the reported AIHlike cases following SARS-CoV-2 vaccination, timing of occurrence of acute hepatitis from vaccination in some of them is very short (less than 7 days), suggesting that a dysregulation of immune system has already occurred before vaccination in those cases. So far, given the availability of only observational literature without a structured collection of AIH-like cases after anti-SARS-CoV-2 vaccines, no definitive conclusions can be drawn. There is a need for populationbased studies to gather data on the incidence, severity, and clinical features of anti-SARS-Cov-2 vaccination-induced AIH under the umbrella of the national and European Scientific Societies.

In the meantime, while intensive vaccination against SARS-CoV-2 continues, healthcare providers should include the diagnosis of AIH triggered by vaccines in the differential diagnosis in cases of acute hepatitis of unexplained etiology and manage them as drug-induced AIH or AIH-like liver injury as recommended by current guidelines [22] .

*These recommendations will be reviewed periodically as further information becomes available.  There is no current evidence to recommend suspension or reduction of immunosuppressive drugs in AIH patients before or immediately after anti-SARS-CoV-2 vaccination.

 The risk of AIH flare or disease worsening following anti-SARS-Cov-2 vaccination has not been assessed to date and specific studies are required before defining a line of recommendation. Based on available data routine testing of transaminases levels in AIH patients after vaccination could be suggested in selected patients although the timing needs to be defined.  Testing of antibody levels for IgM and/or IgG to spike or nucleocapsid proteins to assess immunity to SARS-Cov2 after vaccination in AIH patients is not recommended, nor to assess the need for vaccination in an unvaccinated AIH patients.

managed as suggested by current guidelines and known clinical algorithms, including the indication to liver biopsy. Considering the lack of evidence currently available to exclude drug induced AIH in this setting, immunosuppressive therapy should be carefully considered and used if AIH diagnosis is confirmed; long-term immunosuppressive therapy needs to be assessed on a patient-by-patient basis. 

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

SARS-CoV-2 infection in patients with autoimmune hepatitis

Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Vaccination of patients with autoimmune inflammatory rheumatic diseases

Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases

Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1

A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases

Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up?

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: One or even several swallows do not make a summer

Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination

Genomewide association study identifies variants associated with autoimmune hepatitis type 1

Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions

Pathogens and autoimmune hepatitis

Vaccine-related autoimmune hepatitis: the same disease as idiopathic autoimmune hepatitis? Two clinical reports and review

European Association for the Study of the L. EASL Clinical Practice Guidelines: Autoimmune hepatitis

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine

Autoimmune hepatitis after COVID-19 vaccine -more than a coincidence

Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?

A typical autoimmune hepatitis (AIH) case following Covid-19 mRNA vaccination. More than a coincidence?

Another case of autoimmune hepatitis after SARS-CoV-2 vaccination -still casualty?

Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination: A rare adverse effect?

Auto-immune hepatitis following COVID vaccination

Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality

Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?

Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination

Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination: Need for population-based epidemiological study

Probable autoimmune hepatitis reactivated after COVID-19 vaccination

Clinical features of patients with new onset of autoimmune hepatitis following SARS-CoV-2 vaccination

Liver transplantation following SARS-CoV-2 vaccination-induced liver failure